期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 10, 期 8, 页码 472-484出版社
NATURE PORTFOLIO
DOI: 10.1038/nrclinonc.2013.110
关键词
-
类别
资金
- Fondazione Piemontese per la Ricerca sul Cancro-ONLUS [9970]
- AIRC [MFAG 11349, IG 12812]
- Fondazione Piemontese per la Ricerca sul Cancro-ONLUS grant 'Farmacogenomica-5 per mille MIUR
- European Community' [259015 COLTHERES]
- Intramural Grants Fondazione Piemontese per la Ricerca sul Cancro ONLUS (5 per mille Ministero dell'Istruzione, dell'Universita e della Ricerca)
- Marie-Curie Incoming Fellowship
Cancer is associated with mutated genes, and analysis of tumour-linked genetic alterations is increasingly used for diagnostic, prognostic and treatment purposes. The genetic profile of solid tumours is currently obtained from surgical or biopsy specimens; however, the latter procedure cannot always be performed routinely owing to its invasive nature. Information acquired from a single biopsy provides a spatially and temporally limited snap-shot of a tumour and might fail to reflect its heterogeneity. Tumour cells release circulating free DNA (cfDNA) into the blood, but the majority of circulating DNA is often not of cancerous origin, and detection of cancer-associated alleles in the blood has long been impossible to achieve. Technological advances have overcome these restrictions, making it possible to identify both genetic and epigenetic aberrations. A liquid biopsy, or blood sample, can provide the genetic landscape of all cancerous lesions (primary and metastases) as well as offering the opportunity to systematically track genomic evolution. This Review will explore how tumour-associated mutations detectable in the blood can be used in the clinic after diagnosis, including the assessment of prognosis, early detection of disease recurrence, and as surrogates for traditional biopsies with the purpose of predicting response to treatments and the development of acquired resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据